VREOF (Vireo Growth) Days Payable : 22.33 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Vireo Growth Days Payable?

Vireo Growth's average Accounts Payable for the three months ended in Dec. 2024 was $3.03 Mil. Vireo Growth's Cost of Goods Sold for the three months ended in Dec. 2024 was $12.37 Mil. Hence, Vireo Growth's Days Payable for the three months ended in Dec. 2024 was 22.33.

The historical rank and industry rank for Vireo Growth's Days Payable or its related term are showing as below:

VREOF' s Days Payable Range Over the Past 10 Years
Min: 11.11 Med: 13.46 Max: 20.5
Current: 20.5

During the past 13 years, Vireo Growth's highest Days Payable was 20.50. The lowest was 11.11. And the median was 13.46.

VREOF's Days Payable is ranked worse than
94.91% of 943 companies
in the Drug Manufacturers industry
Industry Median: 85.92 vs VREOF: 20.50

Vireo Growth's Days Payable increased from Dec. 2023 (12.22) to Dec. 2024 (22.33). It may suggest that Vireo Growth delayed paying its suppliers.

Vireo Growth Days Payable Historical Data

The historical data trend for Vireo Growth's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vireo Growth Days Payable Chart

Vireo Growth Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

12.89

12.59

14.17

15.23

15.27

Vireo Growth Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial															12.22	14.95	23.28	26.80	22.33

Competitive Comparison of Vireo Growth's Days Payable

For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vireo Growth's Days Payable Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Days Payable distribution charts can be found below:

* The bar in red indicates where Vireo Growth's Days Payable falls into.

Save Embed

;

Save Embed

;

Vireo Growth Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Vireo Growth's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (1.769	+	2.298)	/	2 )	/	48.613	*	365
=	2.0335					/	48.613	*	365
=	15.27

Vireo Growth's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (3.757	+	2.298)	/	2 )	/	12.371	*	365 / 4
=	3.0275					/	12.371	*	365 / 4
=	22.33

Vireo Growth Days Payable Related Terms

Thank you for viewing the detailed overview of Vireo Growth's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Vireo Growth Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vireo Growth Inc (OTCPK:VREOF) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

0ZF:Germany VREO:Canada

Address

207 South 9th Street, Minneapolis, Minneapolis, MN, USA, 55402

Website

https://www.vireogrowth.com

Vireo Growth Inc is a cannabis company whose mission is to provide safe access, quality products, and value to its customers while supporting its local communities through active participation and restorative justice programs. The company's operating results in one business segment: the cultivation, production, and sale of cannabis.

Executives

Chicago Atlantic Credit Opportunities, Llc	10 percent owner	420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Manager, Llc	10 percent owner	420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Gp Holdings, Llc	10 percent owner	420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Group, Lp	10 percent owner	420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Group Gp, Llc	10 percent owner	420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Advisers, Llc	10 percent owner	420 NORTH WABASH AVENUE, SUITE 500, CHICAGO IL 60611
Joshua Rosen	director	207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Victor E. Mancebo	director	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Christian Gonzales Ocasio	officer: Chief Operating Officer	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Amber Holly Shimpa	director, officer: Chief Administrative Officer	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Patrick Peters	officer: EVP of Retail	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
J Michael Schroeder	officer: General Counsel & CCO	3680 VICTORA STREET N, SHOREVIEW MN 55126
John Andrew Heller	officer: Chief Financial Officer	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Ross Michael Hussey	director	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Judd Theodore Nordquist	director	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402